MX2020007956A - Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. - Google Patents
Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros.Info
- Publication number
- MX2020007956A MX2020007956A MX2020007956A MX2020007956A MX2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- srebp
- compounds
- central ring
- tautomers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan en la presente compuestos que comprenden un núcleo de tres anillos, tales como compuestos de Fórmula (X), Fórmula (X-A), Fórmula (X-Ai), Fórmula (X-B), Fórmula (X-Bi), Fórmula (Z), Fórmula (Z-A), Fórmula (Z-Ai), Fórmula (Z-B), Fórmula (Z-Bi), Fórmula (I), Fórmula (IA), Fórmula (I-Ai), Fórmula (I-B), y Fórmula (I-Bi), y sales, solvatos, tautómeros, isótopos, o isómeros farmacéuticamente aceptables de los mismos; también se proporcionan en la presente métodos para inhibir un componente de la trayectoria de la proteína de unión al elemento regulador de esterol (SREBP), tal como una proteína de activación de disociación de SREBP o SREBP (SCAP), utilizando estos compuestos, o sales, solvatos, tautómeros, isótopos, o isómeros farmacéuticamente aceptables de los mismos; se proporcionan además métodos de tratamiento de un trastorno en un sujeto en necesidad del mismo, tal como enfermedad hepática, esteatohepatitis no alcohólica, resistencia a la insulina, o cáncer. (Ver Fórmulas).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862623405P | 2018-01-29 | 2018-01-29 | |
US201862744397P | 2018-10-11 | 2018-10-11 | |
PCT/US2019/015458 WO2019148125A1 (en) | 2018-01-29 | 2019-01-28 | Srebp inhibitors comprising a 6-membered central ring |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007956A true MX2020007956A (es) | 2021-01-08 |
Family
ID=67395734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007956A MX2020007956A (es) | 2018-01-29 | 2019-01-28 | Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11718628B2 (es) |
EP (1) | EP3746070A4 (es) |
JP (1) | JP2021512160A (es) |
KR (1) | KR20200128531A (es) |
CN (1) | CN112243374A (es) |
AU (1) | AU2019212959A1 (es) |
BR (1) | BR112020015375A2 (es) |
CA (1) | CA3089134A1 (es) |
IL (1) | IL276276A (es) |
MX (1) | MX2020007956A (es) |
SG (1) | SG11202006853PA (es) |
TW (1) | TW201940165A (es) |
WO (1) | WO2019148125A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112243374A (zh) | 2018-01-29 | 2021-01-19 | 卡普勒斯疗法有限责任公司 | 包括6元中心环的srebp抑制剂 |
CN113727732B (zh) | 2019-03-20 | 2023-08-08 | 雷杰纳荣制药公司 | 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高 |
CN110628737B (zh) * | 2019-10-14 | 2022-06-07 | 南京农业大学 | 一个调控黄瓜矮化性状相关基因及其应用 |
EP4058016A4 (en) * | 2019-11-13 | 2023-12-20 | Capulus Therapeutics, LLC | THIOPHENE COMPOUNDS WITH CYCLIC AMIDES AND USES THEREOF |
CN111139294A (zh) * | 2020-01-06 | 2020-05-12 | 中国药科大学 | Fdps在制备治疗非酒精性脂肪性肝炎药物中的应用 |
EP4185584A1 (en) * | 2020-07-24 | 2023-05-31 | Capulus Therapeutics, LLC | Srebp inhibitors comprising a thiophene central ring |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
US20060293339A1 (en) * | 2003-03-24 | 2006-12-28 | Chakravarty Prasun K | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
WO2007002563A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
WO2007005404A1 (en) * | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
GB0625659D0 (en) * | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
EP2120580B1 (en) | 2007-02-02 | 2017-12-27 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US20160221999A1 (en) | 2007-02-02 | 2016-08-04 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
US20110039845A1 (en) * | 2008-04-23 | 2011-02-17 | Kyowa Hakko Kirin Co., Ltd. | 2-aminoquinazoline derivative |
US8563583B2 (en) | 2009-03-09 | 2013-10-22 | Bristol-Myers Squibb Company | Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
US8962623B2 (en) | 2011-03-04 | 2015-02-24 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
ES2617484T3 (es) * | 2012-01-31 | 2017-06-19 | Daiichi Sankyo Company, Limited | Derivado de piridona |
WO2013162061A1 (ja) * | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
US10038143B2 (en) * | 2012-09-14 | 2018-07-31 | Idemitsu Kosan Co., Ltd. | Polymer compound, material for electronic elements, material for organic electroluminescent elements, and organic electroluminescent element |
CN103405429A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
HUE039624T2 (hu) * | 2013-08-28 | 2019-01-28 | Medivation Tech Llc | Heterociklusos vegyületek és alkalmazási eljárások |
BR112016008133B1 (pt) | 2013-11-01 | 2020-11-24 | Novartis Ag | amino-heteroaril benzamidas como inibidores de quinase, seus usos, e composição farmacêutica |
ES2761569T3 (es) * | 2014-04-24 | 2020-05-20 | Novartis Ag | Derivados aminopiridínicos como inhibidores de fosfatidilinositol 3-cinasas |
TWI723572B (zh) * | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
WO2016073826A1 (en) | 2014-11-07 | 2016-05-12 | Fgh Biotech, Inc. | Synthesis of fatostatin based polycyclic compounds |
US10328064B2 (en) * | 2014-12-23 | 2019-06-25 | Fgh Biotech, Inc. | Compositions of fatostatin based heterocyclic compounds and uses thereof |
CA2978627A1 (en) * | 2015-03-04 | 2016-09-09 | Medivation Technologies, Inc. | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
EP3265457A1 (en) * | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Sterol regulatory element-binding proteins (srebps) inhibitors |
US11497738B2 (en) * | 2016-04-29 | 2022-11-15 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
WO2019084681A1 (en) | 2017-10-30 | 2019-05-09 | Montreal Heart Institute | Methods of treating elevated plasma cholesterol |
CN112088157B (zh) | 2017-12-22 | 2023-12-26 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物 |
CN112243374A (zh) | 2018-01-29 | 2021-01-19 | 卡普勒斯疗法有限责任公司 | 包括6元中心环的srebp抑制剂 |
WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
EP3917513A4 (en) | 2019-01-28 | 2022-11-09 | Capulus Therapeutics, LLC | SREBP INHIBITORS WITH A THIOPHENE CENTER RING |
AR118043A1 (es) | 2019-02-11 | 2021-09-15 | Merck Patent Gmbh | DERIVADOS DE INDAZOLIL-ISOXAZOL COMO INHIBIDORES DE c-KIT QUINASA |
EP4058014A4 (en) | 2019-11-13 | 2023-12-13 | Capulus Therapeutics, LLC | SREBP INHIBITOR HAVING A THIOPHENIC RING |
-
2019
- 2019-01-28 CN CN201980023901.3A patent/CN112243374A/zh active Pending
- 2019-01-28 EP EP19743447.5A patent/EP3746070A4/en active Pending
- 2019-01-28 AU AU2019212959A patent/AU2019212959A1/en not_active Abandoned
- 2019-01-28 CA CA3089134A patent/CA3089134A1/en active Pending
- 2019-01-28 MX MX2020007956A patent/MX2020007956A/es unknown
- 2019-01-28 TW TW108103162A patent/TW201940165A/zh unknown
- 2019-01-28 SG SG11202006853PA patent/SG11202006853PA/en unknown
- 2019-01-28 BR BR112020015375-3A patent/BR112020015375A2/pt not_active Application Discontinuation
- 2019-01-28 JP JP2020562085A patent/JP2021512160A/ja active Pending
- 2019-01-28 KR KR1020207024962A patent/KR20200128531A/ko not_active Application Discontinuation
- 2019-01-28 WO PCT/US2019/015458 patent/WO2019148125A1/en unknown
-
2020
- 2020-07-26 IL IL276276A patent/IL276276A/en unknown
- 2020-07-27 US US16/940,212 patent/US11718628B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3746070A4 (en) | 2021-09-01 |
EP3746070A1 (en) | 2020-12-09 |
CN112243374A (zh) | 2021-01-19 |
US20210047340A1 (en) | 2021-02-18 |
CA3089134A1 (en) | 2019-08-01 |
WO2019148125A1 (en) | 2019-08-01 |
BR112020015375A2 (pt) | 2020-12-08 |
KR20200128531A (ko) | 2020-11-13 |
JP2021512160A (ja) | 2021-05-13 |
SG11202006853PA (en) | 2020-08-28 |
AU2019212959A1 (en) | 2020-09-17 |
US11718628B2 (en) | 2023-08-08 |
TW201940165A (zh) | 2019-10-16 |
IL276276A (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020007956A (es) | Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. | |
PH12019501688A1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
EP3820860A4 (en) | PYRIDAZINEG COMPOUNDS TO INHIBIT NAV1.8 | |
WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
MX2022006609A (es) | Compuesto de quinazolina que contiene anillo espiro. | |
MX2018003861A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
MX2017013797A (es) | Inhibidor de janus quinasa. | |
EP4276095A3 (en) | Processes for preparing ask1 inhibitors | |
SG10201804139VA (en) | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
SI4003989T1 (sl) | 6,7-dihidro-5H-pirido(2,3-c)piridazinski derivati in sorodne spojine kot inhibitorji Bcl-xL proteina in proapoptotična sredstva za zdravljenje raka | |
MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
MX2022008100A (es) | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. | |
EP3858182A4 (en) | MAGNETIC BUCKLE | |
WO2020159889A9 (en) | Srebp inhibitors comprising a thiophene central ring | |
MX2019014021A (es) | Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo. | |
WO2013072921A3 (en) | Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds | |
MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
IL287902A (en) | Methods of administering certain vmat2 inhibitors | |
MX2018003860A (es) | Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
WO2016198698A8 (en) | P38 inhibitors for the treatment and prophylaxis of liver cancer | |
EP3822253A4 (en) | PROCESS FOR PREPARING A PROPANDINITRILOXIMETHER COMPOUND AND INTERMEDIATE | |
PH12021550883A1 (en) | Crystalline salts of a plasma kallikrein inhibitor | |
TN2018000118A1 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
SG10202101958YA (en) | Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof |